LENZ Therapeutics, Inc.
LENZ · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $822,998 | $707,693 | $793,712 |
| - Cash | $25,399 | $37,608 | $23,042 | $20,158 |
| + Debt | $461 | $1,051 | $1,182 | $1,381 |
| Enterprise Value | – | $786,441 | $685,833 | $774,935 |
| Revenue | $12,500 | $5,000 | $0 | $0 |
| % Growth | 150% | – | – | – |
| Gross Profit | $12,375 | $5,000 | $0 | $0 |
| % Margin | 99% | 100% | – | – |
| EBITDA | -$16,575 | -$16,838 | -$16,895 | -$15,200 |
| % Margin | -132.6% | -336.8% | – | – |
| Net Income | -$16,700 | -$14,912 | -$14,619 | -$12,652 |
| % Margin | -133.6% | -298.2% | – | – |
| EPS Diluted | -0.59 | -0.53 | -0.53 | -0.46 |
| % Growth | -11.3% | 0% | -15.2% | – |
| Operating Cash Flow | -$8,588 | -$11,508 | -$16,049 | -$9,078 |
| Capital Expenditures | -$439 | -$240 | -$110 | -$149 |
| Free Cash Flow | -$9,027 | -$11,748 | -$16,159 | -$9,227 |